Sodium Citrate Shortage: What Providers and Prescribers Need to Know in 2026

If your patients on Sodium Citrate (Bicitra, Cytra-2, Oracit) are calling your office because they can't fill their prescriptions, you're not alone in hearing this. While Sodium Citrate is not currently declared a formal FDA shortage as of 2026, its liquid formulation and limited manufacturing base create recurring access challenges for patients nationwide. This briefing covers the clinical context, what's driving availability issues, and strategies to help your patients navigate them.

Current FDA Shortage Status

As of early 2026, Sodium Citrate and Citric Acid oral solution is not on the FDA Drug Shortage Database. However, providers should understand that the FDA database captures only formally reported manufacturer-level disruptions. Localized pharmacy-level stock-outs — driven by limited distributors, low-volume ordering, and complex liquid formulation logistics — are ongoing and significantly impact patient access.

Clinical Context: Who Is Prescribed Sodium Citrate?

Sodium Citrate and Citric Acid oral solution is primarily prescribed for:

Metabolic acidosis — especially in chronic kidney disease (CKD) and renal tubular acidosis (RTA). The mechanism is metabolic conversion of citrate to bicarbonate, providing systemic alkalinization without causing systemic alkalosis at standard doses.

Urolithiasis prevention — particularly uric acid stones and calcium oxalate stones where alkalinizing the urine reduces crystallization risk.

Gout management — urinary alkalinization to enhance uric acid excretion, often as adjunctive therapy.

Pre-surgical gastric acid neutralization — as a non-particulate buffer prior to anesthesia.

Why Availability Is Challenging: Supply Chain Factors

Several structural factors contribute to Sodium Citrate's availability challenges:

Concentrated manufacturer base: A small number of manufacturers supply the U.S. market, creating supply vulnerability with any production disruption.

Liquid formulation logistics: Liquid oral solutions are more complex to manufacture and distribute than solid dosage forms, with specialized equipment, shorter shelf lives, and cold chain requirements.

Pharmacy inventory algorithms: Large chain pharmacies use demand-driven ordering systems. Lower-volume specialty medications like Sodium Citrate are often not proactively stocked.

Demand growth: CKD affects approximately 37 million Americans and kidney stone incidence continues to rise, increasing demand for urinary alkalinizers against a relatively fixed supply base.

Clinical Strategies: What Prescribers Can Do

1. Consider Prescribing Equivalent Alternatives

For many patients, Potassium Citrate (Cytra-K oral solution, Urocit-K tablets) is an appropriate therapeutic equivalent. The urinary alkalinizing mechanism is identical; the key clinical consideration is electrolyte profile:

Use Potassium Citrate when sodium restriction is clinically indicated (hypertension, heart failure, edema)

Use Sodium Citrate when potassium restriction is needed (CKD with hyperkalemia, ACE inhibitor or ARB use)

Tricitrates (Cytra-3) for patients without significant sodium or potassium restrictions

Sodium bicarbonate tablets as an alternative alkalinizing agent for metabolic acidosis (not as effective for stone prevention)

2. Prescribe 90-Day Supplies for Chronic Patients

For patients on Sodium Citrate for chronic conditions (CKD, recurrent nephrolithiasis, RTA), prescribing a 90-day supply — especially through mail-order pharmacies — significantly reduces the frequency with which patients must locate stock. This strategy also improves medication adherence.

3. Add Brand Name Cross-References to Prescriptions

When prescribing Sodium Citrate, including a note on the prescription indicating that Bicitra, Cytra-2, Oracit, or any equivalent generic is acceptable can prevent unnecessary refusal at the pharmacy counter and simplify your patients' search.

4. Direct Patients to medfinder

Rather than spending your office staff's time fielding calls about prescription access, consider directing patients to medfinder. medfinder calls pharmacies near the patient to identify which ones can fill the prescription, then texts the results to the patient — reducing friction and freeing up your team's bandwidth.

Key Drug Interactions to Monitor

When managing patients on Sodium Citrate, be alert to the following clinically significant interactions:

Aluminum-containing antacids (Maalox, Gaviscon, Mylanta) — Sodium Citrate dramatically increases aluminum absorption; avoid concurrent use or separate by at least 2-3 hours.

Eltrombopag — Sodium Citrate significantly decreases absorption; contraindicated or separate by at least 4 hours.

Digoxin — Alkalinizing effect increases digoxin levels; monitor closely for toxicity.

Fluoroquinolones, tetracyclines, azole antifungals — Absorption may be reduced; advise 2-hour separation.

Monitoring Parameters

Patients on chronic Sodium Citrate therapy should have periodic monitoring of serum electrolytes (sodium, potassium, bicarbonate), urine pH, and renal function. Urine pH targets for urolithiasis prevention typically range from 6.0 to 7.0, though higher targets may be appropriate for uric acid stone formers. For practical guidance on helping your patients find this medication, see our provider guide to helping patients find Sodium Citrate.